Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor:A prospective single-center double-arm trial

作     者：Boyu Liu Dianxun Fu Yong Fan Zhe Wang Xu Lang Bovu Liu;Dianxun Fu;Yong Fan;Zhe Wang;Xu Lang

作者机构：Department of RadiologyTianjin Medical University General HopitalAnshan Rood 154#Heping DitricTianjin300052China 

出 版 物：《Journal of Interventional Medicine》 (介入医学杂志（英文）)

年 卷 期：2022年第5卷第2期

页      面：89-94页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Irreversible electroporation Radiofrequency ablation Efficacy Intermediate-term survival Prospective trial 

摘      要：Objective:Irreversible electroporation(IRE)is a nonthermal ablation technique for the treatment of malignant liver *** has demonstrated efficacy and safety in the treatment of malignant liver tumors and its unique advantages in the treatment of nearby vascular *** study aimed to compare the efficacy,safety,and intermediate-term outcomes of IRE and radiofrequency(RF)therapy in malignant liver ***:Twenty-four patients with primary or secondary liver malignancies were included in this prospective,double-arm clinical *** were randomly divided into the IRE and RF *** primary outcome was the efficacy(local ablation control evaluation at 90 days).The secondary outcomes were safety(procedure-related complications at≤90 days)and intermediate-term survival(at 24 months).Results:The ablation assessment at 90 days after surgery with m RECIST for IRE versus RF were 70%,20%,0%,and 10%versus 92.9%,7.1%,0%,and 0%(CR,PR,SD,and PD,respectively).The complication rates of IRE versus RF with Clavien-Dindo classification were 16.7%,25%,0%,8.3%,and 8.3%versus 8.3%,50%,0%,0%,and 0%(Grade I,II,Ⅲ,IV,and V,respectively).The average overall survival(OS)was 17.55 months in the IRE group(95%CI 15.13-22.37)and 18.75 months in the RF group(95%CI 12.48-22.61).There was no statistical difference between the IRE and RF groups in terms of efficacy(p=0.48),safety(p=0.887),or 24-month OS(p=0.959).Conclusions:IRE ablation revealed similar efficacy and safety in a short-term follow-up,and similar OS in midterm survival as RF ablation in treating malignant hepatic tumors.